First National Bank of Omaha Purchases New Position in Edwards Lifesciences Corporation $EW

First National Bank of Omaha acquired a new position in shares of Edwards Lifesciences Corporation (NYSE:EW) during the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 41,118 shares of the medical research company’s stock, valued at approximately $3,720,000.

Several other institutional investors and hedge funds also recently modified their holdings of EW. BlackRock Inc. purchased a new position in Edwards Lifesciences in the 2nd quarter worth approximately $5,318,092,000. Bank of New York Mellon Corp acquired a new position in shares of Edwards Lifesciences during the second quarter worth $1,274,082,000. Norges Bank purchased a new position in shares of Edwards Lifesciences in the fourth quarter valued at $803,686,000. Deutsche Bank AG purchased a new position in shares of Edwards Lifesciences in the second quarter valued at $516,552,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in Edwards Lifesciences by 278.3% during the 3rd quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 5,584,646 shares of the medical research company’s stock valued at $434,318,000 after purchasing an additional 4,108,270 shares in the last quarter. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Insider Buying and Selling

In other Edwards Lifesciences news, VP Donald E. Bobo, Jr. sold 23,145 shares of Edwards Lifesciences stock in a transaction that occurred on Wednesday, May 27th. The stock was sold at an average price of $86.42, for a total value of $2,000,190.90. Following the completion of the transaction, the vice president directly owned 98,611 shares in the company, valued at $8,521,962.62. The trade was a 19.01% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, SVP Andrew M. Dahl sold 568 shares of the firm’s stock in a transaction that occurred on Friday, May 29th. The stock was sold at an average price of $86.08, for a total value of $48,893.44. Following the completion of the sale, the senior vice president directly owned 15,334 shares in the company, valued at approximately $1,319,950.72. This trade represents a 3.57% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 25,570 shares of company stock worth $2,219,390 over the last ninety days. 0.31% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on EW shares. Evercore reissued an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Leerink Partners raised Edwards Lifesciences from a “market perform” rating to an “outperform” rating and increased their price target for the company from $87.00 to $101.00 in a report on Friday, July 24th. Royal Bank Of Canada raised their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. UBS Group assumed coverage on Edwards Lifesciences in a report on Tuesday, July 28th. They set a “buy” rating and a $110.00 price objective on the stock. Finally, Wall Street Zen lowered Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Seventeen equities research analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $100.27.

Edwards Lifesciences Stock Up 0.4%

NYSE:EW opened at $91.13 on Wednesday. The company has a market capitalization of $52.47 billion, a price-to-earnings ratio of 52.37, a price-to-earnings-growth ratio of 2.30 and a beta of 0.85. Edwards Lifesciences Corporation has a one year low of $72.30 and a one year high of $96.29. The stock has a 50-day simple moving average of $88.90 and a 200 day simple moving average of $84.49. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings data on Thursday, July 23rd. The medical research company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm had revenue of $1.74 billion for the quarter, compared to analysts’ expectations of $1.70 billion. During the same quarter in the prior year, the firm posted $0.67 earnings per share. Edwards Lifesciences’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Sell-side analysts predict that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.